Delaware, US: July 2, 2023. The management team of Precisio Biotix Therapueutics, a company that develops novel precision biological antibacterial products, is proud to announce that effective July 2, 2023 it is a management owned and controlled company. 

Mark Engel, Chairman and CEO, said“I am very proud of my team for working with me to make this happen.”He added“Our science and scientific teams are fantastic. Our LysiThru™ high throughput lysin screening system is industry leading.  We are confident that we can very rapidly create first or best in class lysins (enzymes that rapidly kill bacteria) to treat some of the most problematic bacterial issues, including killing of bacteria resistant to existing antibiotics.”

Dr. Bryan Li, EVP Medical added“we are primarily focused on lung and skin infections, with an emphasis on antibiotic resistant pathogens or other difficult to treat bacterial infections. We have several products that are ready to start clinical trials now.  For example, our Bactelide™ sustained release multi-phage cocktail, to treat and prevent topical AMR infections, will start a combined phase I/IIb trial as soon as funding is in place. This trial, to be led by Mayo Clinic, is designed to show a significant reduction in the number of infections for patients with pressure injuries.”

For more information on the company, please visit www.precisiobiotix.com.